Regeneron Pharmaceuticals (REGN) and Sanofi (SNY,SAN.PA) announced that the Ministry of Health, Labour and Welfare in Japan has approved Dupixent or dupilumab for the treatment of adults with moderate-to-severe bullous pemphigoid. The approval in Japan is based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial.
Bullous pemphigoid is the seventh approved indication for Dupixent in Japan. It is approved in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, chronic spontaneous urticaria and chronic obstructive pulmonary disease.
At last close, Sanofi shares were down 1.23% to 76.83 euros.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.